Novabridge Biosciences (NBP) FDA Approvals $0.87 +0.05 (+6.04%) As of 12:59 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings Novabridge Biosciences' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Novabridge Biosciences (NBP). Over the past two years, Novabridge Biosciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as VIS-101. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. VIS-101 FDA Regulatory Timeline and Events VIS-101 is a drug developed by Novabridge Biosciences for the following indication: in patients with wet age-related macular degeneration (wet AMD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Dose Update - November 18,2026Dose Update Phase 2bDrug: VIS-101Announced Date: November 18, 2026Indication: in patients with wet age-related macular degeneration (wet AMD).AnnouncementVisara, Inc subsidiary of NovaBridge Biosciences, Inc. announced that the first patient has been dosed in its ASCEND study, a randomized Phase 2b trial designed to evaluate the efficacy, safety and durability of VIS-101, including its potential to enable extended treatment intervals after monthly loading doses, in patients with wet age-related macular degeneration ("wet AMD").AI SummaryVisara, a majority-owned subsidiary of NovaBridge Biosciences, announced that the first patient has been dosed in ASCEND, a Phase 2b trial of VIS-101 for wet age-related macular degeneration (wet AMD). The randomized, masked study will enroll about 244 patients in China and compare VIS-101 at 6 mg or 9 mg with 2 mg aflibercept, an established treatment. After three monthly loading doses, patients may receive further treatment based on set criteria. The study will assess whether VIS-101 can control the disease while allowing treatment intervals of up to seven months. ASCEND builds on a Phase 2a study, in which about half of treatment-naïve patients receiving 6 mg VIS-101 did not need retreatment for six months after their last loading dose. VIS-101 targets two proteins involved in retinal disease. The new trial will further assess its effectiveness, safety and durability, and help select doses for future Phase 3 studies. Longer intervals between injections could reduce the treatment burden for people with wet AMD.Read AnnouncementTop-line results - March 9,2026Top-Line Results Phase 2aDrug: VIS-101Announced Date: March 9, 2026Indication: in patients with wet age-related macular degeneration (wet AMD).AnnouncementNovaBridge Biosciences announced positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).AI SummaryNovaBridge’s VIS-101 is a tetravalent, dual VEGF‑A × ANG‑2 inhibitor designed for retinal vascular diseases. Topline Phase 2a results in wet AMD showed rapid, robust and durable responses: mean best-corrected visual acuity (BCVA) gains exceeded 10 ETDRS letters, with median central subfield thickness (CST) reductions of about 100–150 µm. Both 3 mg and 6 mg dose cohorts produced meaningful improvements, and the compound demonstrated potentially best‑in‑class durability with a favorable safety profile and no dose‑limiting toxicity. The randomized Phase 2a trial enrolled 38 patients in China (ages 50–80), including treatment‑naïve and pre‑treated participants, randomized 2:1 to 6 mg (n=25) vs 3 mg (n=13). Treatment‑related adverse events were low (0% at 3 mg; 8% at 6 mg). A Phase 2b dose‑determining study is expected in H2 2026, with a global Phase 3 program planned for 2027.Read AnnouncementProvided Update - March 3,2026Provided Update Drug: VIS-101Announced Date: March 3, 2026Indication: in patients with wet age-related macular degeneration (wet AMD).AnnouncementNovaBridge Biosciences announced that it will host a virtual business update call on Monday, March 9, 2026, at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in patients with wet age-related macular degeneration (wet AMD).AI SummaryNovaBridge Biosciences will host a virtual business update call on Monday, March 9, 2026, at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in patients with wet age-related macular degeneration (wet AMD). Investors and the public can register and access the live webcast via the News & Events page on the NovaBridge website; a replay will be archived there for at least 90 days. VIS-101 is a purpose-designed, bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor being developed to provide more potent and durable treatment than current standard care. It is being evaluated for wet AMD and is also intended for diabetic macular edema (DME) and retinal vein occlusion (RVO). The candidate is completing a randomized, dose-ranging Phase 2a study for wet AMD. NovaBridge is the majority shareholder of Visara, which holds global development and commercialization rights to VIS-101 outside of Greater China and certain other Asian territories.Read Announcement Novabridge Biosciences FDA Events - Frequently Asked Questions Has Novabridge Biosciences received FDA approval? As of now, Novabridge Biosciences (NBP) has not received any FDA approvals for its therapy in the last two years. What drugs has Novabridge Biosciences submitted to the FDA? In the past two years, Novabridge Biosciences (NBP) has reported FDA regulatory activity for VIS-101. What is the most recent FDA event for Novabridge Biosciences? The most recent FDA-related event for Novabridge Biosciences occurred on November 18, 2026, involving VIS-101. The update was categorized as "Dose Update," with the company reporting: "Visara, Inc subsidiary of NovaBridge Biosciences, Inc. announced that the first patient has been dosed in its ASCEND study, a randomized Phase 2b trial designed to evaluate the efficacy, safety and durability of VIS-101, including its potential to enable extended treatment intervals after monthly loading doses, in patients with wet age-related macular degeneration ("wet AMD")." What conditions do Novabridge Biosciences' current drugs treat? Currently, Novabridge Biosciences has one therapy (VIS-101) targeting the following condition: in patients with wet age-related macular degeneration (wet AMD).. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Actuate Therapeutics FDA EventsEnlivex Therapeutics FDA EventsImmuneering FDA EventsInnate Pharma FDA EventsNovabridge Biosciences FDA EventsOptimi Health FDA EventsRecursion Pharmaceuticals FDA EventsSummit Therapeutics FDA EventsACADIA Pharmaceuticals FDA EventsBiogen FDA EventsEikon Therapeutics FDA EventsGain Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies CytomX Therapeutics FDA Events Arvinas FDA Events Crescent Biopharma FDA Events REGENXBIO FDA Events Monopar Therapeutics FDA Events Eupraxia Pharmaceuticals FDA Events Prothena FDA Events PureTech Health FDA Events Capricor Therapeutics FDA Events C4 Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:NBP last updated on 11/18/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novabridge Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Novabridge Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dose Update - November 18,2026Dose Update Phase 2bDrug: VIS-101Announced Date: November 18, 2026Indication: in patients with wet age-related macular degeneration (wet AMD).AnnouncementVisara, Inc subsidiary of NovaBridge Biosciences, Inc. announced that the first patient has been dosed in its ASCEND study, a randomized Phase 2b trial designed to evaluate the efficacy, safety and durability of VIS-101, including its potential to enable extended treatment intervals after monthly loading doses, in patients with wet age-related macular degeneration ("wet AMD").AI SummaryVisara, a majority-owned subsidiary of NovaBridge Biosciences, announced that the first patient has been dosed in ASCEND, a Phase 2b trial of VIS-101 for wet age-related macular degeneration (wet AMD). The randomized, masked study will enroll about 244 patients in China and compare VIS-101 at 6 mg or 9 mg with 2 mg aflibercept, an established treatment. After three monthly loading doses, patients may receive further treatment based on set criteria. The study will assess whether VIS-101 can control the disease while allowing treatment intervals of up to seven months. ASCEND builds on a Phase 2a study, in which about half of treatment-naïve patients receiving 6 mg VIS-101 did not need retreatment for six months after their last loading dose. VIS-101 targets two proteins involved in retinal disease. The new trial will further assess its effectiveness, safety and durability, and help select doses for future Phase 3 studies. Longer intervals between injections could reduce the treatment burden for people with wet AMD.Read Announcement
Top-line results - March 9,2026Top-Line Results Phase 2aDrug: VIS-101Announced Date: March 9, 2026Indication: in patients with wet age-related macular degeneration (wet AMD).AnnouncementNovaBridge Biosciences announced positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).AI SummaryNovaBridge’s VIS-101 is a tetravalent, dual VEGF‑A × ANG‑2 inhibitor designed for retinal vascular diseases. Topline Phase 2a results in wet AMD showed rapid, robust and durable responses: mean best-corrected visual acuity (BCVA) gains exceeded 10 ETDRS letters, with median central subfield thickness (CST) reductions of about 100–150 µm. Both 3 mg and 6 mg dose cohorts produced meaningful improvements, and the compound demonstrated potentially best‑in‑class durability with a favorable safety profile and no dose‑limiting toxicity. The randomized Phase 2a trial enrolled 38 patients in China (ages 50–80), including treatment‑naïve and pre‑treated participants, randomized 2:1 to 6 mg (n=25) vs 3 mg (n=13). Treatment‑related adverse events were low (0% at 3 mg; 8% at 6 mg). A Phase 2b dose‑determining study is expected in H2 2026, with a global Phase 3 program planned for 2027.Read Announcement
Provided Update - March 3,2026Provided Update Drug: VIS-101Announced Date: March 3, 2026Indication: in patients with wet age-related macular degeneration (wet AMD).AnnouncementNovaBridge Biosciences announced that it will host a virtual business update call on Monday, March 9, 2026, at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in patients with wet age-related macular degeneration (wet AMD).AI SummaryNovaBridge Biosciences will host a virtual business update call on Monday, March 9, 2026, at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in patients with wet age-related macular degeneration (wet AMD). Investors and the public can register and access the live webcast via the News & Events page on the NovaBridge website; a replay will be archived there for at least 90 days. VIS-101 is a purpose-designed, bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor being developed to provide more potent and durable treatment than current standard care. It is being evaluated for wet AMD and is also intended for diabetic macular edema (DME) and retinal vein occlusion (RVO). The candidate is completing a randomized, dose-ranging Phase 2a study for wet AMD. NovaBridge is the majority shareholder of Visara, which holds global development and commercialization rights to VIS-101 outside of Greater China and certain other Asian territories.Read Announcement